OMS405

OMS405 is a **small molecule peroxisome proliferator-activated receptor gamma (PPARγ) agonist** developed primarily by Omeros Corporation for the treatment of addiction-related disorders, including cocaine use disorder, opioid use disorder, tobacco use disorder, and alcoholism[1][2][3][4][5][7][9][10][11]. Its mechanism involves activation of **PPARγ**, which modulates neuronal integrity, reduces craving, and may protect against drug-induced neural damage[2][10][11]. OMS405 has shown efficacy in reducing craving and improving brain white matter in cocaine addiction, as well as reducing anxiety and craving in heroin addiction patients, with minimal side effects[2][10][11]. Patent claims cover the use of any PPARγ agonist, alone or with other therapies, for various forms of addiction[2][11]. OMS405 is a new molecular entity and is not approved for any indications as of the latest development status.

Other names

O-(2-chloro-4-nitrophenyl) O-isopropyl ethylphosphonothioatephosphonothioic acid, ethyl-, O-(2-chloro-4-nitrophenyl) O-(1-methylethyl) esterStauffer N-2404AI 3-25755AI3-25755AI-3-25755ENT 25,755